STREAM-2: Second-line Treatment With REgorafenib in Advanced RAS-Mutant Colorectal Cancer
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
The investigators hypothesize that patients with mCRC RAS-mutant eligible for a second line treatment with good prognostic features, identified as single metastatic site, long progression free survival (PFS) in first line treatment, might benefit from a personalized approach, with less intensive treatment with regorafenib as part of a continuum-of-care strategy aimed at ensuring quality of life and extending survival.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek 18 lat lub więcej
- •Potwierdzony histologicznie rak gruczołowy jelita grubego
- •Rak z przerzutami
- •Mutacja genu RAS potwierdzona badaniem
- •Albo: pierwsze leczenie trwało ponad 6 miesięcy bez powrotu choroby, albo: przerzut w jednym miejscu
- •Ogólny stan zdrowia pozwalający na leczenie (ECOG ≤ 1)
- •Mierzalna choroba widoczna w badaniach obrazowych
- •Przewidywana przeżywalność ponad 12 tygodni
✗ Disqualifies
- •Inny nowotwór w ciągu ostatnich 5 lat (z wyjątkiem raka skóry)
- •Przeciwwskazania do leczenia regorafenibem
- •Niestosowanie immunoterapii, gdy wskazana (przy określonym typie raka)
- •Duża operacja w ciągu 4 tygodni przed zapisem
- •Ciąża lub karmienie piersią
- •Przerzuty do mózgu
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- October 13, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (1)
Istituto Nazionale Tumori | "Fondazione Pascale"
Naples, Italy
Trial contact
Antonio Avallone, MD
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 10/14/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.